Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Trial Profile

Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Aug 2017 Status changed from recruiting to completed.
    • 06 Dec 2016 Results (n=14) assessing safety and tolerability of Elotuzumab presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top